MingMed

MingMed Biotechnology Co., Ltd. is a Chinese enterprise focused on the independent research and development of innovative drugs with global competitiveness. The company has a research and development team composed of several top scientists and experts. Its main product pipelines include ophthalmic drugs, recombinant protein botulinum toxins, tumor immunotherapy drugs, and pet immunotherapy drugs, most of which are breakthrough potential First-in-Class innovative drugs. Additionally, the majority of its leading candidates have entered the clinical stage.